SRC and neoplasm: In contrast, FAT1-knockout tumor cells were significantly more sensitive to the SRC inhibitor dasatinib and SRC/Bcr-Abl inhibitor saracatinib and the CAMK2 inhibitor KN93 as compared to FAT1 wild-type cells.